Market Intelligence, Clinical Progress, and High-Purity Reagents for V-ATPase Modulator and Lysosomal Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ATP6V1E2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ATP6V1E2 Recombinant Protein (Full-Length & Domain-Specific) High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. Theoretical MW ~31 kDa. |
View ATP6V1E2 Products |
| Isoform Control | ATP6V1E1 Recombinant Protein For selectivity screening vs. ubiquitous E1 isoform. Sequence Verified. |
View ATP6V1E1 Products |
| Gene Delivery | ATP6V1E2 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and functional acidification assays. CMV promoter, Puromycin selection. |
View ATP6V1E2 Products |
| Benchmark Ab | Anti-ATP6V1E2 Reference Antibody (Rabbit mAb) Sequence-verified detector for Western blot, IHC, and ICC validation. |
View ATP6V1E2 Products |
| Detection Antibody | Anti-ATP6V1E2 Monoclonal Antibody Recombinant, Sequence Verified. Specific for E2 isoform C-terminal region. |
View ATP6V1E2 Products |
| Validator | ATP6V1E2 siRNA Set (3 unique sequences) For isoform-specific knockdown verification and specificity control. Endotoxin controlled. |
View ATP6V1E2 Products |
| Related Target A | ATP6V0D2 (V0 Subunit d2) Proton channel subunit often co-expressed in cancer. Functional interaction studies. |
View ATP6V0D2 Products |
| Related Target B | ATP6V1A (Catalytic Subunit A) Core catalytic subunit for V-ATPase complex assembly assays. |
View ATP6V1A Products |
| Related Target C | MTOR Synergistic pathway: Lysosomal nutrient sensing and metabolic regulation. |
View MTOR Products |
| Related Target D | ATP6V0C Complex partner: Transmembrane domain subunit for functional co-validation. |
View ATP6V0C Products |
Critical Assay Challenges & TarMart Advantages
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform Selectivity (E2 vs E1) | Purified ATP6V1E1 and ATP6V1E2 proteins available with >95% purity; Sequence Verified for exact isoform discrimination; Homolog panel verified by mass spectrometry. |
| Intracellular Complex Assembly & PPI Mapping | Full-length ORF Lentivirus for physiological expression; Native folding preservation in mammalian cells; Compatible with SPR/BLI and co-crystallization. |
| Lack of Cellular Functional Context | Premade Lentiviral particles for stable overexpression; Preserves native V-ATPase conformation in living cells for functional acidification assays. |
| Genetic Validation of On-Target Pharmacology | Validated siRNA sets (3 unique sequences) included for knockdown verification and rescue assays; Isoform-specific controls to eliminate off-target effects. |
| Lack of Reliable Controls | Recombinant positive control antibodies with verified sequence integrity included; Recombinant proteins from multiple expression systems. |
| Functional ATPase Assay & Reconstitution | High-purity recombinant subunits suitable for in vitro reconstitution studies; Endotoxin <1EU/μg to avoid assay interference. |
Live ATP6V1E2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for V-ATPase modulators is shifting from broad-spectrum pan-V-ATPase inhibitors to isoform-selective V1 subunit targeting. ATP6V1E2, a specialized component of the V1 peripheral domain with restricted expression in renal, neural, and testicular tissues, represents a precision target for indications where ubiquitous V-ATPase inhibition causes unacceptable systemic toxicity. Current research focuses on its aberrant reactivation in metastatic cancers, particularly prostate and lung adenocarcinomas, as well as its emerging role in tumor acidosis and lysosomal dysfunction. As first-generation pan-inhibitors face dose-limiting toxicities, next-generation programs are leveraging ATP6V1E2-selective tools to dissect tissue-specific acidification mechanisms, overcome multidrug resistance in niche tumor microenvironments, and potentially combine with immunotherapy. The next wave of R&D is targeting allosteric sites unique to the E2 isoform to achieve cancer-selective efficacy without systemic toxicity. Additionally, RNAi modalities targeting E2 are being explored to manipulate endosomal acidification, impacting cellular metabolic pathways and viral entry mechanisms.
"The race for ATP6V1E2-selective therapeutics is intensifying, with major players shifting focus from broad-spectrum V-ATPase inhibitors to isoform-specific modulators. As first-generation small molecules enter preclinical validation, the next wave of R&D is targeting allosteric sites unique to the E2 isoform to achieve cancer-selective efficacy without systemic toxicity."
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Preclinical Biotech, Academic Consortia, Oncology Biotechs | Solid Tumors, Neurodegeneration, Metastatic Prostate Cancer, Lung Adenocarcinoma | Isoform Selectivity Assay (Need High-Purity E1 vs E2 Proteins) |
| siRNA / ASO Therapeutics | Emerging RNAi Developers | Oncology, Metabolic Disorders, Testis-Sparing Oncology (fertility preservation) | Knockdown Validation (Need Lentivirus for Stable Cell Lines and Validated siRNA Controls) |
| PROTAC / Degrader | Targeted Degradation Pipelines | Refractory Cancers, Treatment-Resistant Tumors | Ternary Complex Formation (Need Full-Length Native Recombinant Protein) |